Table 2.

Estimates of change from baseline in plasma lipids, cholesterol efflux capacity, and APOA1 and APOB

Variable	1 mg/d	5 mg/d	15 mg/d	Placebo	P, 5 mg/d vs placebo	P, any effect
	N = 22	N = 36	N = 13	N = 32
Lipid panel
Total cholesterol, mg/dL	–16.1 (–25.2 to –6.9)	–16.0 (–23.3 to –8.8)	–13.1 (–24.6 to –1.52)	–7.6 (–15.4 to 0.3)	.10	.34
HDL, mg/dL	–5.2 (–7.6 to –2.7)	–13.4 (–15.4 to –11.5)	–18.3 (–21.4 to –15.3)	–2.2 (–4.3 to –0.1)	< .001	< .001
LDL, mg/dL	–8.1 (–15.9 to –0.3)	–0.2 (–6.3 to 5.9)	7.6 (–2.2 to 17.4)	–5.6 (–12.2 to 1.1)	.22	.055
Triglycerides, mg/dL	–12.0 (–28.2 to 4.2)	–15.2 (–27.7 to –2.6)	–14.0 (–34.2 to 6.3)	2.1 (–11.6 to 15.8)	.053	.23
Hepatic lipase, ng/mL	6.7 (2.0 to 11.5)	18.8 (15.1 to 22.5)	18.3 (12.2 to 24.3)	0.6 (–3.5 to 4.7)	< .001	< .001
APOA1, mg/dL	–15.8 (–24.8 to –6.8)	–22.9 (–30.0 to –15.8)	–39.7 (–50.9 to –28.5)	–0.65 (–8.3 to 7.0)	< .001	< .001
	1 mg/d	5 mg/d	15 mg/d	Placebo	P, 5 mg/d vs placebo	P, any effect
	N = 13	N = 13	N = 13	N = 13
Cholesterol efflux/HDL concentration ratio, % per μmol HDL/L–1	–0.036 (–0.103 to 0.031)	0.070 (0.005 to 0.135)	–0.048 (–0.111 to 0.014)	0.016 (–0.049 to 0.080)	.221	.045
APOB, mg/dL	–6.9 (–14.6 to 0.838)	4.0 (–3.5 to 11.5)	3.5 (–4.0 to 11.0)	–5.2 (–12.8 to 2.4)	.074	.077

Estimated changes from baseline, 95% CIs, and P values extracted from a mixed-model framework for variables with more than 2 visits, from ANCOVA for variables with 2 visits. P values are for comparison of the 5 mg/day arm with placebo group and for the test of any difference between groups in average change over 12-week follow-up.

Abbreviations: ANCOVA, analysis of covariance; HDL, high-density lipoprotein; LDL, low-density lipoprotein.